Médecine

Paramédical

Autres domaines


Suscribirse

CXCL10 release in cardiopulmonary bypass: An in vivo and in vitro study - 20/12/12

Doi : 10.1016/j.biomag.2011.07.001 
Sabino Scolletta a, 1, Andrea Buonamano b, 1, Mariangela Sottili c, Pierpaolo Giomarelli a, Bonizella Biagioli a, Gabriella Barbara Vannelli d, Mario Serio c, Paola Romagnani c, Clara Crescioli e,
a Department of Surgery and Bioengineering, University of Siena, Viale Bracci 1, 53100 Siena, Italy 
b Villa Maria Beatrice Hospital, Via Manzoni 12, 50121 Firenze, Italy 
c Excellence Center for Research, Transfer and High Education (DENOthe), University of Florence, Viale Pieraccini 6, 50139 Florence, Italy 
d Department of Anatomy, Histology and Forensic Medicine, University of Florence, Viale Morgagni 85, 50134 Florence, Italy 
e Department of Health Sciences, Unit of Endocrinology, University of Rome “Foro Italico”, Piazza Lauro de Bosis 15, 00135 Rome, Italy 

Corresponding author. Tel.: +39 06 3673 3387 (branch line: 543).

Abstract

Cardiopulmonary bypass (CPB) leads to systemic and cardiac inflammation. Although the intraoperative blood measurement of some inflammatory cytokines has been recognized as an useful tool in clinical setting, postoperative management still represents a major problem; hence, knowledge about additional possible mediator(s) in time of this process would potentially turn in a clinical benefit. CXCL10 has been shown to be involved in cardiac immune-inflammatory processes. Herein, we aimed to investigate whether and how this chemokine could be a possible early mediator and indicator of inflammation development during CPB. Since cardiac, endothelial and immune cells are all sources of CXCL10, our purpose was also to investigate in vitro CXCL10 secretion pattern in time by those cell types. In thirteen patients undergoing CPB, CXCL10, CXCL9, IL-6, IL-8 and IL-10 have been measured by Elisa in serum withdrawn at eight different perioperative times. Sera from healthy subjects have been tested for comparison. The same cytokines have been measured by Elisa in time-course experiments onto human isolated cardiomyocytes, endothelial and CD4+T cells under inflammatory stimuli. TaqMan Real-Time RT-PCR and immunocytochemistry were used for endothelial cell characterization. CXCL10 level was higher in CPB patients before surgery as compared to healthy subjects; CXCL10 level raises earliest in serum of CPB patients and in isolated cardiomyocytes under inflammatory stimuli as compared to other cytokines. CXCL10 might represent a critical early factor in mediating systemic and local cardiac inflammatory response in subjects undergoing CPB, offering opportunity for future monitoring or therapeutic interventions.

El texto completo de este artículo está disponible en PDF.

Keywords : CXCL10, SIRS, CPB


Esquema


© 2011  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 2 - N° 4

P. 187-194 - octobre 2012 Regresar al número
Artículo precedente Artículo precedente
  • Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic neuropathy in rats
  • Amit D. Kandhare, Kiran S. Raygude, V. Shiva Kumar, Anuchadra R. Rajmane, Asjad Visnagri, Arvindkumar E. Ghule, Pinaki Ghosh, Sachin L. Badole, Subhash L. Bodhankar
| Artículo siguiente Artículo siguiente
  • The expression receptor of peroxisome proliferator-activated receptor gamma (PPARγ) mRNA in human aorta compared to left ventricle in patients with coronary artery disease without diabetes
  • Izabela Wojtkowska, Andrzej Tysarowski, Katarzyna Seliga, Janusz A. Siedlecki, Zbigniew Juraszyński, Janina Stępińska

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.